Brilinta

DRUG2 trials

Sponsors

Seoul National University Hospital, AstraZeneca

Conditions

Acute Coronary SyndromeSickle Cell Disease

Phase 3

Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.

WithdrawnNCT04293172

AstraZenecaSickle Cell Disease

Start: 2020-06-30End: 2022-10-10Updated: 2020-07-15

Unknown Phase

Use of Ticagrelor in Korean ACS Patients: The BRILIANT KOREA Registry

Seoul National University HospitalAcute Coronary Syndrome

Start: 2015-07-31End: 2018-01-31Target: 2000Updated: 2017-10-09